Pluri and ZEO Sign Strategic Collaboration Agreement
Pluri and ZEO have executed a partnership agreement granting ZEO an exclusive license to manufacture and commercialize regenerative medicine biologics in the US using Pluri's manufacturing technology, effective October 26, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed